Protective multi-epitope candidate vaccine for urinary tract infection

Area of Science:

• Microbiology
• Immunology
• Vaccine Development

Background:

• Urinary tract infections (UTIs) are frequently caused by related Gram-negative bacteria, including extraintestinal pathogenic Escherichia coli (ExPEC), Proteus mirabilis, and Klebsiella pneumoniae.
• These pathogens colonize the urinary tract, leading to significant morbidity.

Purpose of the Study:

• To design and evaluate a cross-reactive, multi-epitope vaccine candidate targeting conserved antigens from ExPEC, P. mirabilis, and K. pneumoniae.
• To assess the immunogenicity and protective efficacy of the developed vaccine against these common UTI-causing bacteria.

Main Methods:

• Bioinformatic analysis was employed to identify conserved antigens across the target bacterial genomes.
• A multi-epitope vaccine construct was designed incorporating T-cell (CD8+ and CD4+) and B-cell epitopes.
• Immunogenicity and protective efficacy were evaluated through in vivo experiments.

Main Results:

• The designed vaccine candidate successfully stimulated both CD8+ and CD4+ T-cell responses.
• In vivo studies confirmed the vaccine's ability to induce cross-protective immunity against ExPEC, P. mirabilis, and K. pneumoniae strains.
• The experimental vaccine demonstrated significant protective effects in the tested models.

Conclusions:

• A novel informatics-based vaccine candidate has been successfully designed and validated.
• This multi-epitope vaccine shows promise for broad-spectrum protection against common bacterial causes of UTIs.
• Further development could lead to effective strategies for preventing and managing recurrent UTIs.